Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

33.17 +1.08 (+3.37%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize... 
Via Talk Markets
Alphabet Stock Looks Unbeatable. Here's Why
From cloud growth to enhancements in AI, Alphabet's Q2 earnings had it all. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  On Friday, 73 companies reached new 52-week lows. 
Via Benzinga
Looking At Pfizer's Recent Unusual Options Activity
Via Benzinga
Pfizer (PFE) Q2 2023 Earnings Call Transcript
PFE earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Will AI Take Our Jobs? Pew Research Shines Light On Exposure, Workers At These Corporates Are Vulnerable
Via Benzinga
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.
The company hopes to launch an updated Covid booster shot this fall. But there are several complications. 
Via Investor's Business Daily
Get Out Now! 7 Stocks to Dump After Sorry Q2 Earnings
Investors would be smart to stay away from these companies, each of which has reported disappointing results and seen their share price slump. 
Via InvestorPlace
There Are Signs Of A Slowing Labor Market In New Zealand. The Bank Of Japan Will Continue To Maintain The Stimulus Policy
At the close of the stock exchange yesterday, the Dow Jones Index rose by 0.20%, and the S&P 500 Index fell by 0.27%. The NASDAQ Technology Index closed yesterday negative by 0.43%. 
Via Talk Markets
Capturing Steady Consumer Spending on Health Care with XLV
--News Direct-- 
Via News Direct
Topics ETFs Economy
Exposures Economy
Pfizer Stock Dips As Waning Demand For Covid Products Slashes Sales In Half
Pfizer's sales fell by more than half in the second quarter, while earnings plummeted. 
Via Investor's Business Daily
Pfizer Earnings Preview
Via Benzinga
GSK, Pfizer Lock Horns Over Patent Fight Related To Respiratory Syncytial Virus Vaccine
GSK Plc (NYSE: GSK) has sued Pfizer Inc (NYSE: PFE) in Delaware court, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's four patent rights in its RSV  
Via Benzinga
S&P 500 Forecast: Resilience In Earnings Season
The S&P 500 experienced a minor pullback during Tuesday's trading session, characterized by the market's ongoing noisy behavior. Despite this, the 4500 level beneath continues to provide essential... 
Via Talk Markets
Fear & Greed Index Moves To 'Greed' Zone After S&P 500 Settles Lower
U.S. stocks closed mixed on Tuesday, as investors digested recent earnings reports and a fresh batch of economic data. 
Via Benzinga
Exact Sciences, A Cathie Wood Darling, Just Reported A Sixth Big Sales Quarter
The company is a leader in using diagnostics to screen for early cancer cases. 
Via Investor's Business Daily
Mixed Brew: Pfizer, Merck Earnings Head Opposite Ways, But Uber And Caterpillar Slug Line Drives
(Tuesday market open) The new month starts with stocks tinted red, but this week’s main events are just getting underway. A rise in Treasury yields might have investors nervous early Tuesday as the... 
Via Benzinga
US Stocks Mixed; Pfizer Earnings Beat Views
U.S. stocks were mixed this morning, with the Dow Jones trading slightly higher on Tuesday. Following the market opening Tuesday, the Dow traded up 0.03% to 35,568.68 while the NASDAQ fell 0.57% to... 
Via Benzinga
Pfizer Takes Over 50% Hit In Q2 Sales As COVID-19 Related Revenues Dwindle, Tightens Annual Outlook
Pfizer Inc (NYSE: PFE) has reported a Q2 adjusted EPS of $0.67, down 67% Y/Y, but beating the consensus of $0.57. 
Via Benzinga
Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023
These discounted blue-chip stocks boast robust underlying businesses which present amazing long-term upside potential ahead 
Via InvestorPlace
Nasdaq, S&P 500 Futures Pullback After Strong July; Why This Analyst Recommends Staying Fully Invested
Via Benzinga
Pfizer, AMD And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading slightly higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Markets Remain Bullish After S&P 500 Rises For Fifth Consecutive Month
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed higher on Monday, recording gains for the month of July. The S&P 500 gained 3.1% to record its... 
Via Benzinga
Why Novavax Stock Zoomed 13% Higher on Monday
A renewed fight against COVID-19 might be coming. 
Via The Motley Fool
7 Stocks to Buy Before They Surpass 2021 Highs
These 7 stocks to watch before new peaks are approaching 2021 highs and should move past those levels sometime this year. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Earnings Extravaganza: Another One-Third Of S&P 500 Companies Report This Week, Including Amazon, Apple
(Monday market open) It’s “tech week” on Wall Street. No, wait, it’s “pharma week.” Or is it “employment week?” How about all three? 
Via Benzinga
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next. 
Via The Motley Fool
7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. 
Via InvestorPlace
If You Can Only Buy 1 Blue-Chip Stock, It Better Be One of These Names
These three essential blue-chip stock picks come with solid business models, a good reputation, and strong financials. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.